NASDAQ:ANTH - Anthera Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0770 0.00 (0.00 %)
(As of 09/23/2018 04:00 PM ET)
Previous Close$0.0770
Today's Range$0.0740 - $0.0849
52-Week Range$0.07 - $2.97
Volume65,238 shs
Average Volume1.38 million shs
Market Capitalization$2.07 million
P/E Ratio-0.02
Dividend YieldN/A
Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Receive ANTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio3.31
Quick Ratio3.31


Trailing P/E Ratio-0.02
Forward P/E Ratio-0.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$140,000.00
Price / Sales14.40
Cash FlowN/A
Price / CashN/A
Book Value($0.42) per share
Price / Book-0.18


EPS (Most Recent Fiscal Year)($3.75)
Net Income$-26,870,000.00
Net MarginsN/A
Return on Equity-3,347.91%
Return on Assets-366.62%


Outstanding Shares26,180,000
Market Cap$2.07 million

Anthera Pharmaceuticals (NASDAQ:ANTH) Frequently Asked Questions

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH."

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Shares of Anthera Pharmaceuticals reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) posted its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Zacks' consensus estimate of ($0.82) by $0.09. View Anthera Pharmaceuticals' Earnings History.

When is Anthera Pharmaceuticals' next earnings date?

Anthera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, September, 26th 2018. View Earnings Estimates for Anthera Pharmaceuticals.

What price target have analysts set for ANTH?

4 brokerages have issued 1-year target prices for Anthera Pharmaceuticals' stock. Their forecasts range from $0.50 to $10.00. On average, they expect Anthera Pharmaceuticals' stock price to reach $5.25 in the next year. This suggests a possible upside of 6,718.2% from the stock's current price. View Analyst Price Targets for Anthera Pharmaceuticals.

What is the consensus analysts' recommendation for Anthera Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anthera Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Anthera Pharmaceuticals.

Who are some of Anthera Pharmaceuticals' key competitors?

Who are Anthera Pharmaceuticals' key executives?

Anthera Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul F. Truex, Exec. Chairman (Age 49)
  • Mr. John Craig Thompson, Pres, CEO & Director (Age 51)
  • Dr. Renee Martin Ph.D., Sr. VP of Medical Sciences (Age 49)
  • Dr. William R. Shanahan Jr., M.D., J.D., Chief Medical Officer & Sr. VP (Age 69)
  • Ms. May Liu, Chief Accounting Officer, Sr. VP of Fin. & Admin. and Compliance Officer (Age 42)

How do I buy shares of Anthera Pharmaceuticals?

Shares of ANTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of ANTH stock can currently be purchased for approximately $0.0770.

How big of a company is Anthera Pharmaceuticals?

Anthera Pharmaceuticals has a market capitalization of $2.07 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-26,870,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. Anthera Pharmaceuticals employs 21 workers across the globe.

What is Anthera Pharmaceuticals' official website?

The official website for Anthera Pharmaceuticals is

How can I contact Anthera Pharmaceuticals?

Anthera Pharmaceuticals' mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company can be reached via phone at 510-856-5600.

MarketBeat Community Rating for Anthera Pharmaceuticals (NASDAQ ANTH)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  536
MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel